(Q37758453)

22 August 2017

1 reference

title

Psoriatic arthritis: pharmacotherapy update (English)

1 reference

22 August 2017

0 references

1 reference

Philip J Mease

1

1 reference

22 August 2017

publication date

1 August 2010

1 reference

Current Rheumatology Reports

22 August 2017

published in

1 reference

22 August 2017

volume

12

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

272-280

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-010-0108-z

22 August 2017

exact match

0 references

cites work

Methotrexate and histologic hepatic abnormalities: a meta-analysis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-010-0108-Z

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

21 January 2018

1 reference

12 December 2020

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2

1 reference

12 December 2020

Therapies for axial disease in psoriatic arthritis. A systematic review.

1 reference

12 December 2020

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

1 reference

12 December 2020

Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis

1 reference

12 December 2020

Interleukin-15: a new cytokine target for the treatment of inflammatory diseases

1 reference

12 December 2020

Outcome measures in psoriatic arthritis

1 reference

12 December 2020

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

1 reference

12 December 2020

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

12 December 2020

Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology

1 reference

12 December 2020

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

12 December 2020

Psoriatic arthritis assessment tools in clinical trials

1 reference

12 December 2020

Biologic therapies for psoriasis. A systematic review

1 reference

12 December 2020

Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death

1 reference

12 December 2020

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

1 reference

12 December 2020

Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis

1 reference

12 December 2020

Treatment recommendations for psoriatic arthritis.

1 reference

12 December 2020

Consensus on a core set of domains for psoriatic arthritis

1 reference

12 December 2020

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

12 December 2020

Genetics of psoriasis and psoriatic arthritis: update and future direction.

1 reference

12 December 2020

Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines

1 reference

12 December 2020

Biological biomarkers in psoriatic disease. A review.

1 reference

12 December 2020

International spondyloarthritis interobserver reliability exercise - the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis

1 reference

12 December 2020

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

1 reference

12 December 2020

Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference

1 reference

12 December 2020

Psoriatic arthritis screening tools

1 reference

12 December 2020

Psoriasis assessment tools in clinical trials

1 reference

12 December 2020

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

12 December 2020

Conventional systemic agents for psoriasis. A systematic review.

1 reference

12 December 2020

Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Therapies for psoriatic enthesopathy. A systematic review.

1 reference

12 December 2020

International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures

1 reference

12 December 2020

Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis

1 reference

12 December 2020

Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome.

1 reference

12 December 2020

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

1 reference

12 December 2020

Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria

1 reference

12 December 2020

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

1 reference

12 December 2020

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

1 reference

12 December 2020

International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis

1 reference

12 December 2020

Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design

1 reference

12 December 2020

Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility

1 reference

12 December 2020

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

12 December 2020

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

1 reference

12 December 2020

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

12 December 2020

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

12 December 2020

Therapies for peripheral joint disease in psoriatic arthritis. A systematic review

1 reference

12 December 2020

Assessment tools in psoriatic arthritis.

1 reference

12 December 2020

Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis

1 reference

12 December 2020

Therapies for psoriatic nail disease. A systematic review

1 reference

12 December 2020

Therapies for dactylitis in psoriatic arthritis. A systematic review

1 reference

12 December 2020

Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective

1 reference

12 December 2020

Psoriatic arthritis therapy: NSAIDs and traditional DMARDs.

1 reference

12 December 2020

Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).

1 reference

12 December 2020

Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.

1 reference

12 December 2020

Associations of 25 structural, degradative, and inflammatory candidate genes with lumbar disc desiccation, bulging, and height narrowing

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1002/ART.24268

10.1007/S11926-010-0108-Z

30 October 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference